Yawei Wang,Binlin Tang,Lei Long,Peng Luo,Wei Xiang,Xueru Li,Huilan Wang,Qingzhi Jiang,Xu Tan,Shenglin Luo,Huijuan Li,Ziwen Wang,Zelin Chen,Yu Leng,Zhongyong Jiang,Yang Wang,Le Ma,Rui Wang,Chunyu Zeng,Zujuan Liu,Yu Wang,Hongming Miao,Chunmeng Shi

Abstract:Abstract Pro-inflammatory activation of adipose tissue macrophages (ATMs) is causally linked to obesity and obesity-associated disorders. A number of studies have demonstrated the crucial role of mitochondrial metabolism in macrophage activation. However, there is a lack of pharmaceutical agents to target the mitochondrial metabolism of ATMs for the treatment of obesity-related diseases. Here, we characterize a near-infrared fluorophore (IR-61) that preferentially accumulates in the mitochondria of ATMs and has a therapeutic effect on diet-induced obesity as well as obesity-associated insulin resistance and fatty liver. IR-61 inhibits the classical activation of ATMs by increasing mitochondrial complex levels and oxidative phosphorylation via the ROS/Akt/Acly pathway. Taken together, our findings indicate that specific enhancement of ATMs oxidative phosphorylation improves chronic inflammation and obesity-related disorders. IR-61 might be an anti-inflammatory agent useful for the treatment of obesity-related diseases by targeting the mitochondria of ATMs.

Improvement of obesity-associated disorders by a small-molecule drug targeting mitochondria of adipose tissue macrophages